Treatment

Lecanemab and what this means for the future treatment of Alzheimer’s disease 2:24
Lecanemab and what this means for the future treatment of Alzheimer’s disease
Jesse Cedarbaum • 1 Dec 2022
Ensuring the safety of epigenome therapies in the treatment of Alzheimer’s disease 1:13
Ensuring the safety of epigenome therapies in the treatment of Alzheimer’s disease
Ornit Chiba-Falek • 6 Dec 2022
Future direction for anti-amyloid immunotherapies 5:40
Future direction for anti-amyloid immunotherapies
Nicolas Villain • 6 Dec 2022
What’s next for clinical trials in Alzheimer’s disease? 1:54
What’s next for clinical trials in Alzheimer’s disease?
Jesse Cedarbaum • 1 Dec 2022
Precision medicine in Alzheimer’s treatment: genetics and co-pathologies 3:18
Precision medicine in Alzheimer’s treatment: genetics and co-pathologies
Nicolas Villain • 6 Dec 2022
Lipidomics as a tool for dementia research 1:06
Lipidomics as a tool for dementia research
Hussein Yassine • 30 Nov 2022
Nilotinib: a potential repurposed treatment for Alzheimer’s disease? 3:53
Nilotinib: a potential repurposed treatment for Alzheimer’s disease?
Charbel Moussa • 28 Nov 2022
Personalized approach to dementia prevention and treatment 1:37
Personalized approach to dementia prevention and treatment
Hussein Yassine • 30 Nov 2022
The Phase III NILEAD trial: nilotinib as a novel treatment for AD 5:02
The Phase III NILEAD trial: nilotinib as a novel treatment for AD
Charbel Moussa • 28 Nov 2022
The future of SAGE-718 in Alzheimer’s disease treatment 1:52
The future of SAGE-718 in Alzheimer’s disease treatment
Aaron Koenig • 28 Nov 2022
The impact of TKIs on miRNA expression in the treatment of AD 4:11
The impact of TKIs on miRNA expression in the treatment of AD
Charbel Moussa • 2 Dec 2022
Insights into the upcoming LIGHTWAVE trial using SAGE-718 to treat patients with MCI and early AD 1:42
Insights into the upcoming LIGHTWAVE trial using SAGE-718 to treat patients with MCI and early AD
Aaron Koenig • 28 Nov 2022
The COCOA Trial: can multimodal lifestyle interventions treat AD? 4:39
The COCOA Trial: can multimodal lifestyle interventions treat AD?
Jared Roach • 22 Nov 2022
New mechanisms to treat Alzheimer’s disease by targeting the NMDA pathway 1:00
New mechanisms to treat Alzheimer’s disease by targeting the NMDA pathway
Aaron Koenig • 28 Nov 2022
Long-term transdermal nicotine for the treatment of mild cognitive impairment 4:37
Long-term transdermal nicotine for the treatment of mild cognitive impairment
Paul Newhouse • 23 Nov 2022
The PreventE4 study: testing omega-3 supplementation in APOE4 carriers before the onset of dementia 3:06
The PreventE4 study: testing omega-3 supplementation in APOE4 carriers before the onset of dementia
Hussein Yassine • 30 Nov 2022
The content of VJDementia is intended for healthcare professionals